EMEA recommends Teva organ rejection drugs - report

The drugs are generic version's of Roche's CellCept.

"Reuters" reports that the European Medicines Agency (EMEA) has recommended approval of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) generic versions of the organ rejection drug CellCept, Myfenax and Mycophenolate mofetil Teva. Both versions are indicated for preventing acute transplant rejection in patients receiving kidney, heart, or liver transplants.

The two medicines are generic versions of Roche Holding AG's (SWX: ROG) original drug CellCept, which the EMEA approved in 1996. "Reuters" noted that marketing recommendation by the EMEA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

Teva closed at $44.40 on Nasdaq on Friday, giving a market cap of $34 billion. The share rose 0.3% in after-hours trading, and fell 1% at the opening on the TASE today.

Published by Globes [online], Israel business news - www.globes-online.com - on December 16, 2007

© Copyright of Globes Publisher Itonut (1983) Ltd. 2007

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018